Pancreatin + L-Ornithine L-AspartateThird Party Manufacturing in India

This fixed-dose combination brings together two complementary mechanisms for comprehensive digestive and hepatic support. Pancreatin provides the three essential pancreatic enzymes protease, amylase, and lipase that hydrolyze proteins, carbohydrates, and fats respectively, restoring normal digestive function in patients with exocrine pancreatic insufficiency. L-Ornithine L-Aspartate (LOLA) is a stable salt of two naturally occurring amino acids that works through an entirely different mechanism. Ornithine activates the urea cycle in periportal hepatocytes by serving as a substrate for ornithine transcarbamoylase and activating carbamoyl phosphate synthetase, the rate-limiting enzyme of the urea cycle. Aspartate provides carbon skeletons for perivenous glutamine synthesis. Together, these amino acids enhance ammonia detoxification through two major metabolic pathways: urea synthesis in the liver and glutamine synthesis in the liver and skeletal muscle. By lowering blood ammonia levels, LOLA helps prevent hepatic encephalopathy in patients with chronic liver disease. The combination of digestive enzymes with a hepatoprotective agent is particularly valuable for patients with pancreatic insufficiency secondary to liver disease.

Therapeutic Uses

Pancreatin + L-Ornithine L-Aspartate is prescribed for the treatment of:

• Pancreatic insufficiency with hepatic involvement: Patients with chronic pancreatitis who also have elevated ammonia levels or early hepatic encephalopathy benefit from the dual action of digestive enzymes and ammonia reduction.
• Chronic pancreatitis with malnutrition: Addresses both maldigestion caused by enzyme deficiency and metabolic disturbances associated with concurrent liver dysfunction.
• Post-operative pancreatic and hepatic support: Used in recovery following pancreatic or biliary surgery where both digestive and hepatic function may be compromised.

Why Manufacturers Choose Pancreatin + L-Ornithine L-Aspartate

This combination product represents a specialized niche in the Indian pharmaceutical market, where there is significant demand for multi-action digestive and hepatoprotective formulations. India has a high prevalence of both pancreatitis and liver disease, creating a substantial patient population that can benefit from this combination. The product is well-established in the PCD franchise model, with strong demand from gastroenterologists and hepatologists. Pancreatin (CAS 8049-47-6) and L-Ornithine L-Aspartate (CAS 3230-94-2) are both readily available from Indian API manufacturers. The tablet formulation at 100mg+150mg strength is the standard. Manufacturers targeting this segment benefit from limited competition compared to single-molecule digestive enzyme products, allowing for better pricing and margin realization in the third party manufacturing market.